The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer
- PMID: 25793413
- PMCID: PMC4368615
- DOI: 10.1371/journal.pone.0121535
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer
Abstract
Purpose: Aromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.
Methods: Genotyping for CYP19 rs4646 variants was performed on 406 Chinese women with stage I-II and operable stage III breast cancer. Associations were evaluated between CYP19 rs4646 genotypes and disease-free survival (DFS).
Results: In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041). These differences were further demonstrated by a multivariate analysis (HR = 0.456, 95 % CI = 0.249-0.836, P = 0.011). Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002). Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).
Conclusions: The present study indicates that CYP19 rs4646 polymorphism is related to DFS in early breast cancer and that the prognosis index of the homozygous for the minor allele (AA) may depend on menopause status. The findings are novel, if confirmed, rs4646 genotypes may provide useful information for routine management in breast cancer.
Conflict of interest statement
Figures



Similar articles
-
S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):5309-17. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191232 Free PMC article.
-
The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.Oncologist. 2008 Jul;13(7):751-60. doi: 10.1634/theoncologist.2007-0246. Epub 2008 Jul 9. Oncologist. 2008. PMID: 18614591
-
CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer.Biomed Res Int. 2013;2013:562197. doi: 10.1155/2013/562197. Epub 2013 Nov 14. Biomed Res Int. 2013. PMID: 24324964 Free PMC article.
-
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.BMC Med. 2015 Jun 11;13:139. doi: 10.1186/s12916-015-0373-9. BMC Med. 2015. PMID: 26067721 Free PMC article.
-
The association between CYP19 polymorphism and endometriosis risk: a system review and meta-analysis.Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:42-8. doi: 10.1016/j.ejogrb.2016.01.010. Epub 2016 Jan 21. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 26897397 Review.
Cited by
-
Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450.J Pers Med. 2020 Aug 28;10(3):108. doi: 10.3390/jpm10030108. J Pers Med. 2020. PMID: 32872162 Free PMC article. Review.
References
-
- Zhao Y, Mendelson CR, Simpson ER (1995) Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol Endocrinol 9: 340–349. - PubMed
-
- Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, et al. (2003) The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 86: 219–224. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases